TARA-002 Phase 2b/3 clinical trial enrollment rates and interim data readouts for IFALD indication
FDA regulatory interactions including orphan drug designation maintenance, breakthrough therapy designation applications, and pre-NDA meeting outcomes
Cash runway extensions through equity financings, ATM offerings, or non-dilutive partnerships/licensing deals
Competitive landscape developments in IFALD treatment space and alternative parenteral nutrition approaches
low - Clinical trial execution and FDA regulatory timelines are largely insulated from GDP fluctuations. Patient enrollment for rare disease trials depends on disease prevalence and physician referral patterns at academic medical centers, not discretionary spending. However, macro conditions indirectly affect: (1) ability to raise capital in public/private markets during risk-off environments, (2) acquisition appetite from strategic buyers during economic downturns, (3) hospital budget constraints affecting clinical trial site participation. Rare disease focus provides defensive characteristics as treatments address life-threatening conditions with limited alternatives.
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of future cash flows from potential drug approvals 5-7 years out, disproportionately impacting pre-revenue biotech valuations. (2) Risk-free rate competition makes speculative clinical-stage equities less attractive versus bonds, driving multiple compression. (3) Tighter financial conditions reduce access to growth capital and increase dilution risk when raising funds. (4) Biotech sector correlation with Nasdaq growth stocks amplifies rate-driven selloffs. Current 13.69x current ratio provides buffer, but eventual need for capital raises makes cost of capital critical. Rate cuts would be positive catalyst.
Binary clinical trial outcomes with TARA-002 Phase 2b/3 data representing existential catalyst - trial failure would eliminate primary value driver and likely trigger strategic alternatives review
Ultra-orphan market size constraints limit peak revenue potential to $150-300M annually even with high penetration, reducing strategic acquirer interest and standalone commercial viability
FDA regulatory pathway uncertainty for novel mechanism in rare disease with limited precedent, potential for additional trials or endpoints beyond current development plan
growth/speculative - Attracts biotech-focused hedge funds, venture capital crossover investors, and retail traders seeking asymmetric risk/reward from binary clinical catalysts. Recent 116% six-month return and 67% one-year return demonstrate momentum characteristics. Not suitable for value or income investors given no revenue, negative cash flow, and high volatility. Investor base consists of: (1) specialized healthcare funds with rare disease expertise, (2) event-driven funds playing clinical trial catalysts, (3) retail investors attracted to orphan drug narratives. Negative ROE (-35%) and ROA (-37%) confirm pure speculation on future approval value rather than current fundamentals.
Trend
-9.8% vs SMA 50 · +3.2% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $24.9M $24.9M–$24.9M | — | -$1.26 | — | ±10% | High7 |
FY2026(current) | $22.3M $22.3M–$22.3M | ▼ -10.3% | -$1.40 | — | ±17% | High7 |
FY2027 | $25.3M $25.3M–$25.3M | ▲ +13.6% | -$1.33 | — | ±20% | High5 |
INSTITUTIONAL OWNERSHIP
TARA News
About
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
TARA◀ | $5.10 | -3.77% | $197M | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.08% | — | 50.3 | +398824.8% | -4085.6% | 1500 |